Company / Total Debt
Idexx Laboratories Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$450.0M
FY2025
5-year range
$450.0M / $850.7M
FY2021-FY2025
Trend
-27.2%
vs FY2024
Sector context
#67 of 102
Health Care
What the data says
At $450M, Idexx Laboratories's total debt ranks #36 of 102 in the Health Care sector. Total Debt has declined for 5 consecutive years, from $909M in FY2020 to $450M in FY2025.
Based on SEC 10-K filings.
$450M in FY2025 with a 5-year CAGR of -13.1%.
Improved from $698M to $450M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- -13.1%
- 10-Year CAGR
- -
Sector benchmark
#36 of 102 in Health CareTop 34% of 102This company $450.0M Sector average $4.5B
▼
-90.0% below sector average
Key checks
Key Insights
- Idexx Laboratories's total debt has declined for 5 consecutive years.
- 5-year CAGR of -13.1%, indicating a declining trend.
- In FY2025, total debt decreased 27.2% year-over-year.
- Ranks #67 out of 102 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $450.0M | -27.2% |
| FY2024 | $617.8M | -11.5% |
| FY2023 | $698.2M | -9.3% |
| FY2022 | $769.8M | -9.5% |
| FY2021 | $850.7M | -6.4% |
| FY2020 | $909.1M | +30.0% |
| FY2019 | $699.4M | +16.2% |
| FY2018 | $601.8M | -0.8% |
| FY2017 | $606.6M | +2.2% |
| FY2016 | $593.7M | -0.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026